Decoding Lung Cancer: How Combined Cell Types Impact Treatment
"A New Study Explores the Genetic Landscape of Combined Small Cell and Non-Small Cell Lung Cancers"
Lung cancer remains a leading cause of cancer-related deaths worldwide. It's broadly classified into two main types: non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases, and small cell lung cancer (SCLC), representing about 15%. While these categories help guide treatment, some patients have tumors with a combination of both cell types, known as combined SCLC/NSCLC.
Treating combined SCLC/NSCLC is particularly challenging. Often, NSCLC is treated with targeted therapies that address specific mutations within the cancer cells, while SCLC is more responsive to chemotherapy. However, in combined cases, it's unclear how these different components interact and whether targeted therapies will be effective. Understanding the genetic profiles of these combined cancers is critical for developing better treatment strategies.
A new study published in Lung Cancer delves into the genetic characteristics of combined SCLC/NSCLC tumors. Researchers analyzed tissue samples from patients with both newly diagnosed combined cancers and adenocarcinomas that transformed into SCLC after initial treatment. By comparing the genetic make-up of the different cell types within these tumors, the study provides valuable insights into how these combined cancers develop and respond to treatment.
Lung Cancer's Current Burden
The SEER Cancer Stat Facts report lists a lung and bronchus cancer incidence rate of 47.2 cases per 100,000 people per year and a death rate of 30.2 per 100,000. U.S. Cancer Statistics reported 228,058 new lung cancers in the United States in 2023 and 128,663 lung cancer deaths in 2024. A 2025 analysis of 1,584,746 lung cancer cases found that 188,426, or 11.9%, were small-cell lung cancer (SCLC), while SCLC accounted for 11.2% of all lung cancer cases in the report.
Treatment Standards and Constraints
For extensive metastatic SCLC, the reported standard of care is combination chemotherapy with cisplatin and etoposide plus immunotherapy. The National Cancer Institute notes that standard-treatment results for NSCLC are poor except in the most localized cancers. SCLC treatment is also constrained by the difficulty some patients have tolerating invasive tissue-sampling procedures, while immunotherapy has shown limited success in SCLC despite becoming a standard of care.
From Tobacco History to Tumor Origins
The history of SCLC is often connected to the broader history of tobacco: a review identifies 1492, when Christopher Columbus received tobacco described as certain dried leaves from Native Americans, as one milestone. The NCI's cancer-research timeline includes 1775, when chimney soot was linked with squamous cell carcinoma, as well as 1863, when inflammation and cancer were connected. More recently, researchers have questioned the long-held belief that SCLC arose from specialized lung cells, describing its cellular origins as an area of continuing investigation.
What Did the Researchers Discover About Combined Lung Cancers?
The study involved a detailed analysis of tumor samples from eight patients. Four had newly diagnosed combined SCLC/NSCLC, while the other four initially had lung adenocarcinoma that later transformed into SCLC after treatment with tyrosine kinase inhibitors (TKIs). TKIs are drugs that target specific proteins in cancer cells to stop their growth.
- Genetic Consistency: Both the SCLC and NSCLC components within the combined tumors often shared similar mutations, particularly in genes like EGFR, TP53, and RB1.
- TP53 and RB1 Inactivation: The inactivation of TP53 and RB1 genes appears to be an early event in the development of combined SCLC/NSCLC. These genes normally suppress tumor growth, so their inactivation promotes cancer development.
- ASCL1 Activation: The SCLC component often showed activation of the ASCL1 pathway, which is known to play a role in the development of SCLC.
- PI3K/AKT1 Signaling: Activating mutations involving the PI3K/AKT1 signaling pathway were frequently observed in the SCLC component. This pathway is involved in cell growth and survival, and its activation can contribute to cancer development and resistance to therapy.
Incremental Progress in SCLC
A 2025 review reports that adding immune checkpoint inhibitors to first-line chemotherapy for extensive-stage SCLC has produced modest survival improvements. A Yale summary describes research in which combined chemotherapy, radiotherapy, and immunotherapy improved survival rates. At the same time, preclinical work is examining how SCLC cells develop resistance to both chemotherapy and immunotherapy, including mechanisms that help the cells evade treatment.
Why Early Responses Do Not End the Fight
Traditional chemotherapy drugs share important limitations, including nonspecific targeting and low bioavailability, according to a 2023 review. SCLC is highly chemosensitive and can respond quickly to systemic therapy, but patients commonly develop relapse. These limitations show why an initial response should not be confused with durable disease control.
SCLC and NSCLC Follow Different Clocks
The National Cancer Institute lists surgery, chemotherapy, radiation therapy, laser therapy, and targeted therapy among treatment options for SCLC. SCLC generally requires a faster treatment pace than NSCLC because its tumors can spread quickly. NSCLC is described as slower growing, more likely to be found earlier, and associated with additional options such as surgery and targeted therapy.
What Does This Mean for Patients?
This research provides a deeper understanding of the genetic underpinnings of combined SCLC/NSCLC. This knowledge can help doctors make more informed decisions about treatment, particularly when considering targeted therapies.
The Current Extensive-Stage Framework
Expert discussions of extensive-stage SCLC emphasize first-line platinum-based chemotherapy combined with a PD-L1 inhibitor. Another clinical update describes the usual regimen as platinum chemotherapy plus etoposide and immunotherapy, followed by additional treatment. Together, these sources present combination systemic therapy as the central contemporary approach for extensive-stage disease.
A Broader NSCLC Development Pipeline
Future-facing discussions of NSCLC treatment describe a dynamic market landscape and emphasize the need to understand the disease landscape and forecast. One market summary estimates that the NSCLC therapeutics market was valued at approximately $33 billion in 2025 and anticipates significant compound annual growth through 2036. This projection describes a market outlook, not a guaranteed clinical outcome.
An Immunologically Cold Tumor
SCLC remains difficult to treat with anti-PD-L1 therapy alone. Clinical commentary characterizes SCLC as an immunologically cold tumor, a description that helps explain why single-agent immune approaches can be challenging. This framing underscores the broader need to understand the tumor environment rather than relying on one treatment mechanism.
Relapse, Age, and Individual Response
Although limited-stage SCLC therapy is delivered with curative intent, a real-world study reports that most patients relapse and eventually die from recurrent disease. A case report of a 75-year-old female smoker with advanced SCLC and an ECOG performance status of 2 describes a response to treatment. Real-world cases also highlight the clinical importance of combination therapy: in IMpower133, adding PD-L1 therapy to standard chemotherapy improved survival in patients with extensive-stage SCLC.
The study also sheds light on why some combined SCLC/NSCLC tumors may not respond well to TKIs, even if they have EGFR mutations. The presence of other mutations, particularly those involving the PI3K/AKT1 pathway, may contribute to resistance.
While more research is needed, these findings suggest that a comprehensive genetic analysis of both the SCLC and NSCLC components is crucial for tailoring treatment to individual patients. This may involve repeat biopsies or larger surgical specimens to ensure accurate assessment of the tumor's genetic make-up. As research continues, new therapies that target the specific pathways involved in combined SCLC/NSCLC may offer improved outcomes for patients with this challenging disease.